Analyst Rating Update on Globus Medical (GMED)

Globus Medical (GMED) : Zacks Investment Research ranks Globus Medical (GMED) as 3, which is a Hold recommendation. 5 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. Not everyone is convinced about the stocks future, hence, the stock receives 1 Sell recommendation. A total of 5 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 11 research analysts is 2.18, which indicates as a Buy.

Globus Medical (GMED) : Currently there are 8 street experts covering Globus Medical (GMED) stock. The most bullish and bearish price target for the stock is $33 and $23 respectively for the short term. The average price target of all the analysts comes to $27.38. The estimated standard deviation from the target is $3.11.

For the current week, the company shares have a recommendation consensus of Buy.


Globus Medical (NYSE:GMED): The stock opened at $23.47 on Wednesday but the bulls could not build on the opening and the stock topped out at $23.62 for the day. The stock traded down to $23.25 during the day, due to lack of any buying support eventually closed down at $23.38 with a loss of -0.47% for the day. The stock had closed at $23.49 on the previous day. The total traded volume was 821,533 shares.

Globus Medical, Inc. is a medical device company. The Company is focused on developing products for patients with musculoskeletal disorders and spine disorders. Its products consist of two categories: Innovative Fusion and Disruptive Technologies. Innovative Fusion products comprise fusion products to treat various spinal disorders for the entire spine and can be used in various surgical approaches. Disruptive Technologies represents a shift in the treatment of spinal disorders by allowing for surgical procedures and the treatment of spinal disorders. The Companys portfolio of Disruptive Technology products includes products that allow for minimally invasive surgical (MIS) techniques, as well as treatment alternatives, including motion preservation technologies, such as dynamic stabilization, total disc replacement and interspinous process spacer products, and biomaterials technologies, as well as interventional pain management solutions.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.